Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer
10.1007/s00432-013-1465-6
Saved in:
Main Authors: | Chan, D., Zheng, Y., Tyner, J.W., Chng, W.J., Chien, W.W., Gery, S., Leong, G., Braunstein, G.D., Koeffler, H.P. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/116934 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
by: Yong, W.P., et al.
Published: (2014) -
Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling
by: Wang, Lingzhi, et al.
Published: (2020) -
A simple and sensitive high-performance liquid chromatographic method for quantification of PXD101, a histone deacetylase inhibitor in human plasma
by: Zhang, N., et al.
Published: (2011) -
Histone deacetylase 3 (hdac3) is specifically required for liver development in zebrafish
by: Farooq, M., et al.
Published: (2014) -
Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells
by: Ong, P.-S., et al.
Published: (2014)